List of Drugs for an Urgent Public Health Need

The List of Drugs for an Urgent Public Health Need (the List) contains the following drug-related details: the brand name, the medicinal ingredient(s), the route of administration, the strength, the dosage form and the identifying code or number, if any, assigned in the country in which the drug was authorized for sale.

The List also contains other information obtained through the public health official notification, including: the foreign regulatory authority which authorized the drug, the foreign country from which the drug can be imported, the Canadian jurisdiction notifying for the drug (i.e., the Canadian jurisdiction in which the drug is allowed to be sold), the urgent public health need for the drug, the intended use or purpose of the drug (i.e., the purpose for which the drug must be used in the Canadian jurisdiction) and the date of notification by a public health official.

A public health official notification allows a listed drug to be imported into Canada and sold in the notifying jurisdiction for a period of 1 year. If a notification has not been renewed by a public health official within one year of the initial notification, the drug will no longer be eligible for importation and sale. Drugs may also be removed from the List at any time at the Minister's discretion.

A drug is only eligible for importation and sale if all columns on the List are populated, including columns located under the "For Information Purposes" subheading.

(PDF Version - 139 KB, 4 pages)

List of Drugs for an Urgent Public Health Need
Brand name Medicinal ingredient(s) Dosage form Strength Route of administration Foreign identifying code or number For Information Purposes
Foreign regulatory authority / Foreign country Canadian jurisdiction notifying for the drug Urgent public health need Applicable Foreign Authorised Indication (Intended use or purpose of the drug) Date of notification by a public health official
Diaphin i.v. diamorphine Injectable 10 g/vial Intravenous 55561 Swissmedic / Switzerland British Columbia Opioid crisis Substitution therapy in case of severe heroin dependence as part of a treatment program with prescription heroin. June 7,
2018
Diaphin IR 200 diamorphine Tablet 200 mg Oral 57724 Swissmedic / Switzerland British Columbia Opioid crisis June 7,
2018
Diaphin SR 200 diamorphine Tablet 200 mg Oral 57720 Swissmedic / Switzerland British Columbia Opioid crisis June 7,
2018
Priftin rifapentine Tablet 150 mg Oral 0088-2100-24 FDA / USA First Nations and Inuit Health Branch Tuberculosis crisis For the treatment of latent tuberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in  patients at high risk of progression to TB disease. June 8,
2018
Priftin rifapentine Tablet 150 mg Oral 0088-2100-24 FDA/USA Newfoundland/Labrador Tuberculosis crisis For the treatment of latent tuberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in patients at high risk of progression to TB disease. July 18, 2018
Priftin rifapentine Tablet 150 mg Oral 0088-2102-24 FDA/USA British Columbia Tuberculosis crisis For the treatment of latent tuberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in patients at high risk of progression to TB disease. August 8, 2018
Priftin rifapentine Tablet 150 mg Oral 0088-2100-24 FDA/USA Nunavut Tuberculosis crisis For the treatment of latent turberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in  patients at high risk of progression to TB disease. August 3, 2018
Priftin rifapentine Tablet 150 mg Oral 0088-2100-24 FDA/USA Manitoba Tuberculosis crisis For the treatment of latent turberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in  patients at high risk of progression to TB disease. September 6, 2018
Priftin rifapentine Tablet 150 mg Oral 0088-2102-24 FDA/USA Public Health Agency of Canada - for use in Correctional Service Canada Facilities Tuberculosis crisis For the treatment of latent turberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in patients at high risk of progression to TB disease. December 12, 2018
Suboxone buprenorphine hydrochloride; naloxone hydrochloride Film 2 mg/0.5 mg;
8 mg/2 mg;
12 mg/3 mg
Buccal, Sublingual 12496-1202-3;
12496-1208-3;
12496-1212-3
FDA/USA Public Health Agency of Canada - for use in Correctional Service Canada Facilities Opioid crisis For the treatment of opioid dependence and as part of a complete treatment plan to include counseling and psychosocial support. December 12, 2018
Sublocade buprenorphine Injectable 100 mg/0.5 ml
300 mg/1.5 ml
Subcutaneous

12496-0100-1
12496-0300-1

FDA/USA Public Health Agency of Canada - for use in Correctional Service Canada Facilities Opioid crisis For the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine containing-product, followed by dose adjustment for a minimum of 7 days December 12, 2018
Priftin rifapentine Tablet 150 mg Oral 0088-2100-24 FDA/USA Yukon Tuberculosis crisis For the treatment of latent turberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in patients at high risk of progression to TB disease November 2, 2018
Priftin rifapentine Tablet 150 mg Oral 0088-2100-24 FDA/USA Alberta Tuberculosis crisis For the treatment of latent turberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in patients at high risk of progression to TB disease. November 20, 2018
Priftin rifapentine Tablet 150 mg Oral 0088-2102-24 FDA/USA Northwest Territories Tuberculosis crisis For the treatment of latent turberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in patients at high risk of progression to TB disease. January 7, 2019
Priftin rifapentine Tablet 150 mg Oral 0088-2100-24 FDA/USA Ontario Tuberculosis crisis For the treatment of latent turberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in patients at high risk of progression to TB disease. March 21, 2019
Priftin rifapentine Tablet 150 mg Oral 0088-2100-24 FDA/USA Saskatchewan Tuberculosis crisis For the treatment of latent turberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in patients at high risk of progression to TB disease. November 21, 2018

Related Information:

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: